Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer's Disease (AD)

Posted On: 2019-11-30 16:58:51

SUVN-502 did not meet the pre-specified primary endpoint

Meaningful improvements and potential beneficial effects on cognitive function, behavioral and neuropsychiatric end points were emerged based on subgroup analyses.

SUVN-502 was safe and well tolerated with no significant adverse events

Suven Life Sciences announces top-line results from its Phase 2A proof of concept study evaluating the efficacy, safety and tolerability of Masupirdine (SUVN-502). The first of its kind trial which focused on advanced stage AD patients (moderate AD) who are currently treated with standard of care Donepezil and Memantine. The unique triple-therapy (Masupirdine+ Donepezil+ Memantine) design was based on efficacy results in pre-clinical cognition models in which masupirdine enhances the effects of combined treatment with Donepezil and Memantine.

The primary efficacy endpoint of the trial is change from baseline to Week 26 in ADAS-Cog 11 score. The secondary outcome measures are MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, safety and tolerability assessment.

Findings of this Phase 2A study:

- Masupirdine (SUVN-502) is safe and well tolerated without significant adverse events.

- Triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

- Subgroup analyses on cognition, function, behavioral, neuropsychiatric inventory and secondary endpoints revealed interesting, statistically significant and potentially beneficial data sets.

- Potential beneficial effects and statistically significant results with Masupirdine treated groups on cognition emerged upon considering combinations of Patients Age, Memantine regimen, Memantine plasma concentration, Memantine treatment duration and Alzheimer's disease duration.

- Sub-population of Masupirdine treated patients showed significant improvement and statistically significant reduction in the behavioral symptoms in the domains of agitation / aggression and delusions /hallucination as assessed by the NPI subscale scores.

- Detailed study outcomes of the above findings will be presented through one oral and six poster presentations at Clinical Trials on Alzheimer's Disease (CTAD) being held at San Diego from 4th - 7th December 2019.

We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502) says Venkat Jasti, CEO of Suven.

Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.314.05 as compared to the previous close of Rs. 312.75. The total number of shares traded during the day was 52597 in over 1718 trades.

The stock hit an intraday high of Rs. 317.6 and intraday low of 309.85. The net turnover during the day was Rs. 16529894.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Adani Transmission Limited receives LoI for Transmission Project in the State of Maharashtra

R Systems International Limited Board approves interim dividend of Rs. 1.50 for 2019

Prabhat Technologies launches parenteral control mobile application

Karnataka Bank launches KBL Xpress Car Loan

Aditya Vision Ltd opens 41st showroom

Hester Biosciences Ltd board to consider fund raising through issue of equity shares

Ashiana Housing Ltd announces conversion of EoI into booking for Phase 1 of 'Ashiana Aditya'

CARE A1+ rating assinged to Shree Cement's Commercial Paper

ABANS ENTERPRISES LTD announces resignation of CFO

RIL arm acquires 51.78% stake in Asteria

REC Ltd transfers stake in Rampur Sambhal Transco Limited to Powergrid

Wipro Promax Analytics Solutions recognised by Promotion Optimization Institute

Zensar participates in the 'Women in the Workplace 2019' report by McKinsey and LeanIn.Org

AU Bank announces the completion of Temasek's investment for 4.8% stake

BGR Energy Systems bags order from TANGEDCO

Acuite Ratings reaffirms A3+ rating for Dynacons' short term instruments

Premier Explosives Ltd receives license from Telangana Government

Kansai Nerolac dedicates an exclusive installation to Visakhapatnam under its 'Breathing City' initiative

TCS wins CII Industrial IP Award for Best Patents Portfolio

Metropolis Healthcare wins Patient Experience Team of the Year award

Mastek Limited sells its partial stake in Majesco to drive growth strategy

UFO Moviez Unveils New Brand Identity to Reinforce its Cinema Advertising Offering

Infosys Ltd updates on class action lawsuit

Magma Fincorp raises INR 350 Cr. from FMO - the Dutch Development Bank

Majesco Ltd to increase stake in Majesco USA to 74.6%

Smt. Usha Sangwan ceased to be nominee director of AXIS Bank Ltd

Vipin Sondhi appointed as MD & CEO of Ashok Leyland

Let us not forget our Fundamental duties in the clamour for Fundamental Rights

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

IDEGO and EdgeVerve Join Hands to Drive RPA Adoption Across Latin America

Brickwork reaffirms ratings of SRG Housing Finance Limited

Sambhaav Media Ltd commences FM Radio Station at Bhaderwah (J&K) (94.3 MHz)

Embassy Group's HR Practices and Workplace Culture earns Top Rank in the Industry

Persistent Systems announces new leadership for unified Salesforce practice in Europe

Navin Fluorine International Ltd plans capex at Dahej, Gujarat

Datamatics to Strategically Divest its Stake in Cignex Datamatics Inc.

Aster DM Healthcare Ltd increases stake in Prerana Hospital Ltd to 86.99%

Kesar Enterprises Ltd accepts OTS with Allahabad Bank, UCO Bank

South African Depository Consolidates All Operations on to TCS BaNCS™ for Market Infrastructure

One of the leading Global Business Process Outsourcing Company Goes Live on Ramco

Wipro wins the '2019 SUSE Global System Integrator Partner of the Year' award

Infosys Awarded the 'Excellent Partner Award' by Mazda

Bank of Baroda allots 65,14,65,798 shares to Government of India

CreditAccess Grameen Wins the Prestigious 'Microfinance Organization of the Year' Award

INOX Leisure Limited commences operations of multiplex at Orion Mall, Gorakhpur

Wipro awarded Cloud and Infrastructure Transformation Partnership Contract by OlymPus

More than 50 percent of Enterprises look at Cloud Applications as a Foundation for Digital Transformation - Infosys Research

HT Media Ltd's Long term rating downgraded to 'CRISIL AA / Stable'

Sterling and Wilson Solar Ltd's subsidiary receives order of approx. Rs. 827 crore

Hikal Ltd receives EIR from US FDA for Panoli facility, shares surge







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019